Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns “Buy” Rating from Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $425.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target would suggest a potential upside of 106.83% from the company’s current price.

Several other brokerages have also weighed in on ALNY. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Friday, July 10th. Needham & Company LLC lowered their price target on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Citigroup began coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $445.48.

Alnylam Pharmaceuticals Stock Down 28.3%

Shares of Alnylam Pharmaceuticals stock opened at $205.48 on Friday. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The business’s 50 day simple moving average is $289.80 and its 200-day simple moving average is $312.07. The stock has a market capitalization of $27.43 billion, a price-to-earnings ratio of 56.14 and a beta of 0.27. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business’s revenue was up 96.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.44) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Geneos Wealth Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the period. Flow Traders U.S. LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $241,000. Daiwa Securities Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 703 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter adjusted earnings of $1.84 per share, above one consensus estimate of $1.63, while revenue rose 66.9% year over year to $1.29 billion. The earnings call also highlighted continued strength in TTR medicines and progress in the company’s broader pipeline. Alnylam Q2 2026 Earnings Call Shows TTR Strength
• Positive Sentiment: Needham lowered its price target to $357 from $510 but maintained a “Buy” rating, indicating the analyst still views the recent weakness as excessive and sees substantial potential upside. Needham price target update
• Neutral Sentiment: Alnylam’s recently presented Alzheimer’s RNAi data and quarterly revenue above $1 billion provide additional pipeline and commercial support, although these developments have not offset the immediate outlook concerns. Alnylam Alzheimer’s RNAi data
• Negative Sentiment: Revenue of $1.29 billion fell short of the $1.32 billion consensus estimate, and another estimate placed quarterly EPS at $1.84 versus $2.05 expected. The mixed results suggest that growth is not keeping pace with elevated investor expectations. Alnylam Q2 earnings and revenue estimates
• Negative Sentiment: The company issued 2026 revenue guidance of $5.3 billion to $5.7 billion, with management citing normalized demand for second-line Amvuttra use. Investors viewed the outlook reduction as the primary catalyst for the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: A law firm announced a securities-fraud investigation into Alnylam on behalf of shareholders. The announcement is an allegation and does not establish wrongdoing, but it adds legal and reputational overhang. Alnylam securities fraud investigation

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.